During earnings season, there is a specific type of corporate optimism that manifests itself when a company not only exceeds expectations but also pushes up its own forecast for the third consecutive year, practically challenging analysts to continue doubting it. That’s roughly what happened on April 30, when Cardinal Health, the Dublin, Ohio-based drug and medical-supply distributor, reported fiscal third-quarter revenue of $60.9 billion, up 11% from a year earlier, and raised its full-year profit outlook again.
A headline like that is simple to ignore. Particularly in a sector that transports pills and gauze pads by the truckload rather than headlines by the hour, revenue figures in the tens of billions tend to blend together. But sit with the details for a minute, and something more interesting takes shape: a healthcare supply chain that spent much of the past several years lurching from one disruption to the next — pandemic shortages, freight bottlenecks, tariff whiplash — finally showing signs of settling into something steadier.
Non-GAAP diluted earnings per share jumped 35% to $3.17, and the company narrowed its full-year guidance upward to a range of $10.70 to $10.80 a share. That’s the kind of self-assurance that is rarely unintentionally displayed. Investors seem to believe it, too; shares moved higher in the days following the report, even as some of the underlying GAAP numbers told a messier story underneath the surface.
And they did. GAAP operating earnings actually fell 30%, to $509 million, weighed down by a $184 million goodwill impairment tied to Navista, part of the company’s physician-services ambitions. It’s the kind of writedown that tends to get buried beneath the better headline figures, and reasonably so — non-GAAP numbers, stripped of one-time charges, are what most of Wall Street watches closely. Still, it’s hard not to notice that even a quarter framed as triumphant came bundled with a quiet admission that one corner of the growth strategy needed pruning.
The real engine, as it has been for years now, was the Pharmaceutical and Specialty Solutions segment, where revenue climbed 11% to $56.1 billion and segment profit rose 18% to $784 million. Specialty pharmaceuticals alone grew more than 20%, and GLP-1 weight-loss drugs — the Ozempic-and-Wegovy category that has quietly reshaped entire pharmaceutical supply chains over the past two years — contributed roughly six percentage points of that growth on their own. There’s something almost symbolic about watching a century-old distributor’s fortunes rise on the back of a drug class that barely existed in its current form five years ago.
However, not all of the segments were brilliant. The division of the company that deals with Cardinal-branded medical supplies, Global Medical Products and Distribution, reported flat revenue close to $3.1 billion and a 36% decline in segment profit to just $25 million, primarily due to tariff costs. The company has already paid about $200 million in IEPA-related tariffs this fiscal year, according to executives. Refunds may be possible in light of a recent court decision, but they are not assured. Whether that money returns, when it might, and how much is distributed to customers in the event that it does are still unknown.
When reading the transcript of the earnings call, what strikes me is how casual CEO Jason Hollar seemed about it all. Almost in passing, he brought up the winter storms and supply interruptions that occurred during the quarter, portraying them as challenges that the operation overcame rather than crises that caused it to fail. He attributed the company’s “durability and resilience” to an outstanding third quarter that continued its momentum. Perhaps executives only use that language when making these calls. Reading between the lines, however, suggests that record service levels during a truly difficult winter had some internal significance—proof that the logistics apparatus had become more resilient since the turbulent years that everyone in this industry all too well remembers.
Additionally, Cardinal Health continued to make debt payments, retiring a $100 million term loan ahead of schedule, and increasing its year-to-date share repurchases to $1 billion. As a result, the company’s leverage ratio was 3.0 times, comfortably within its targeted range. That’s not glamorous at all. On financial Twitter, it won’t become popular. However, it’s the kind of quiet discipline that, in the long run, tends to matter more than the headline figure for any given quarter.
It’s still worthwhile to consider whether this is a true turning point for healthcare distribution in general or just one business succeeding in a still-rough sector. The issue of tariff policy remains unresolved. The Navista impairment suggests that there is still a strategic recalibration going on in the background. However, a quarter built on increased guidance, declining debt, and segment profit growth across almost every line appears, at the very least, to be a significant step toward something calmer—and perhaps, just possibly, the early shape of normal—for a sector that spent years absorbing shocks it never chose.
